Investment Rating - The report rates the pharmaceutical industry as "stronger than the market" based on its relative performance compared to the benchmark indices [4]. Core Insights - The pharmaceutical sector has shown resilience, with the SW Pharmaceutical Biotechnology Index increasing by 1.56% during the week of March 23-29, outperforming the CSI 300 Index [2]. - The implementation of a nationwide long-term care insurance system in China is expected to stimulate investment opportunities in the silver-haired care industry, benefiting over 330 million disabled individuals [2]. - The acquisition of Connoa by Gilead for up to $2.175 billion highlights the validation of a new model for Chinese innovative drugs entering international markets [2]. Summary by Sections Industry Performance - The pharmaceutical index experienced significant fluctuations, with leading sectors including CXO (+6.12%), raw materials (+5.34%), and chemical preparations (+2.88%), while blood products (-2.95%) and vaccines (-2.36%) lagged behind [2]. Long-term Care Insurance - The long-term care insurance system will cover all employees and residents, with a uniform rate of approximately 0.3%, providing essential care and financial support for disabled individuals [2]. - Since its pilot in 2016, the long-term care insurance has attracted over 60 billion yuan in social capital investments into related industries [2]. Investment Opportunities - The report emphasizes the potential for investment in sectors such as gloves and vitamins due to price increases, while maintaining a long-term positive outlook on the Chinese pharmaceutical industry's innovation trajectory [2]. - Key areas for investment include ADCs, bispecific antibodies, small nucleic acids, and weight-loss drugs, with specific companies highlighted for their promising prospects [2].